董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heinz Mausli | 男 | Independent Director | 63 | 47.99万美元 | 未持股 | 2026-04-30 |
| Gerard Ber | 男 | Independent Director | 68 | 46.58万美元 | 4.39 | 2026-04-30 |
| Julie H. McHugh | 女 | Independent Director | 61 | 55.26万美元 | 3.38 | 2026-04-30 |
| Gary J. Pruden | 男 | Independent Director | 64 | 49.24万美元 | 2.83 | 2026-04-30 |
| James H. Thrall | 男 | Independent Director | 82 | 48.89万美元 | 3.84 | 2026-04-30 |
| Minnie V. Baylor Henry | 女 | Independent Director | 78 | 48.08万美元 | 1.26 | 2026-04-30 |
| Phuong Khanh Morrow | 女 | Independent Director | 52 | 55.47万美元 | 未持股 | 2026-04-30 |
| Minnie V. Baylor Henry | 男 | Independent Director | 78 | 未披露 | 未持股 | 2026-04-30 |
| Julie M. Eastland | 女 | Independent Director | 61 | 47.66万美元 | 未持股 | 2026-04-30 |
| Mary Anne Heino | 女 | Director,Executive Chair and Chief Executive Officer | 66 | 217.39万美元 | 67.17 | 2026-04-30 |
| Samuel Leno | 男 | Independent Director | 80 | 48.93万美元 | 6.17 | 2026-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Marshall, Jr. | 男 | Chief Financial Officer and Treasurer | 59 | 519.50万美元 | 9.86 | 2026-04-30 |
| Jamie Spaeth | -- | Chief People Officer | 44 | 未披露 | 未持股 | 2026-04-30 |
| Daniel M. Niedzwiecki | 男 | Chief Administrative Officer, General Counsel and Corporate Secretary | 49 | 496.64万美元 | 7.01 | 2026-04-30 |
| Jean Claude Provost | -- | Chief Scientific Officer | 63 | 348.53万美元 | 1.36 | 2026-04-30 |
| Amanda Morgan | 女 | Chief Commercial Officer | 47 | 330.45万美元 | 1.14 | 2026-04-30 |
| Cheryl Ball | 女 | Chief Strategy Officer and Head of Corporate Development | 59 | 未披露 | 未持股 | 2026-04-30 |
| Ludger Dinkelborg | 男 | Head of Research and Development | 63 | 1525.96万美元 | 未持股 | 2026-04-30 |
| Mary Anne Heino | 女 | Director,Executive Chair and Chief Executive Officer | 66 | 217.39万美元 | 67.17 | 2026-04-30 |
董事简历
中英对照 | 中文 | 英文- Heinz Mausli
-
Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently. - Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
- Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently.
- Gerard Ber
-
Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG. - Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
- Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG.
- Julie H. McHugh
-
Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade(infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University. - Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
- Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade(infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University.
- Gary J. Pruden
-
GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015. - GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
- Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015.
- James H. Thrall
-
James H.Thrall自2018年2月起担任董事，提名和公司治理委员会成员以及科学和技术委员会主席。Thrall博士目前在哈佛医学院（Harvard Medical School）担任杰出的Juan M.Taveras放射学教授，并从1988年到2013年担任马萨诸塞州总医院放射学系主任。在此之前，萨尔博士在1983年至1988年期间担任亨利福特医院放射学主席，在那里他还担任医生受托人，并担任亨利福特医务人员Vice Chairman of the Board。Thrall博士是美国国家医学研究院（National Academy of Medicine）的成员，曾在许多美国和国际医学和专业协会担任领导和董事会职位。Thall博士于1968年在密歇根大学（University of Michigan）获得医学博士学位，并在华盛顿特区沃尔特·里德陆军医学中心（Walter Reed Army Medical Center）接受放射学和核医学培训。
James H. Thrall is a Director, a member of the Nominating and Corporate Governance Committee and the Chairperson of the Science and Technology Committee, serving on the Board since February 2018. Dr. Thrall currently holds the Distinguished Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988 where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981. - James H.Thrall自2018年2月起担任董事，提名和公司治理委员会成员以及科学和技术委员会主席。Thrall博士目前在哈佛医学院（Harvard Medical School）担任杰出的Juan M.Taveras放射学教授，并从1988年到2013年担任马萨诸塞州总医院放射学系主任。在此之前，萨尔博士在1983年至1988年期间担任亨利福特医院放射学主席，在那里他还担任医生受托人，并担任亨利福特医务人员Vice Chairman of the Board。Thrall博士是美国国家医学研究院（National Academy of Medicine）的成员，曾在许多美国和国际医学和专业协会担任领导和董事会职位。Thall博士于1968年在密歇根大学（University of Michigan）获得医学博士学位，并在华盛顿特区沃尔特·里德陆军医学中心（Walter Reed Army Medical Center）接受放射学和核医学培训。
- James H. Thrall is a Director, a member of the Nominating and Corporate Governance Committee and the Chairperson of the Science and Technology Committee, serving on the Board since February 2018. Dr. Thrall currently holds the Distinguished Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988 where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981.
- Minnie V. Baylor Henry
-
Minnie V. Baylor Henry，自2021年6月起担任Paratek Pharmaceuticals, Inc.董事会成员。自2015年以来，贝勒-亨利女士一直担任B-Henry & Associates的总裁，该公司是一家专注于为生命科学公司提供监管和合规战略服务的咨询公司。在担任现职之前，她曾在2011年至2015年期间担任强生（强生）医疗器械和诊断业务的全球监管事务副总裁。在2011年回到强生之前，贝勒-亨利女士曾在德勤担任监管和资本市场咨询全国总监，在监管生命科学领域有着成功的实践经验。从1999年到2008年，她在强生的制药和消费者业务部门担任过许多行政领导职务，包括担任强生负责非处方药业务的医疗和监管事务副总裁。在加入强生之前，贝勒-亨利曾在美国食品和药物管理局（FDA）工作。在FDA的职业生涯中，她担任过许多职务，最著名的是FDA的National Health欺诈协调员，以及在药品中心担任药品营销、广告和传播司司长。Baylor-Henry曾担任食品和药品法律研究所（FDLI）的董事会主席，也是Flame Biosciences的董事会成员。此外，她还担任药物信息协会（DIA）的主席和理事会主席，目前担任该协会的研究员。Baylor-Henry女士是霍华德大学的受托人，也是霍华德大学药学院访问委员会主席。此外，她还是scPharmaceuticals、Apyx Medical、Lantheus控股和PolarityTE的独立董事，这些公司都是上市公司。贝勒-亨利女士是多家非盈利公司的董事会成员，包括The Partnership、Mass Eye & Ear Hospital和Dress for Success Boston。贝勒-亨利在霍华德大学药学院获得药学学位，在天主教大学哥伦布法学院获得法学学位。
Minnie V. Baylor Henry,has served on Paratek Pharmaceuticals, Inc. Board since June 2021. Ms. Baylor-Henry has served as the President of B-Henry & Associates, a consulting firm focused on providing regulatory and compliance strategy services to life sciences companies, since 2015. Prior to assuming her current role, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson's (J&J) Medical Devices & Diagnostics business from 2011 to 2015.Before returning to J&J in 2011, Ms. Baylor-Henry was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche, with a successful practice that focused on regulatory life sciences. From 1999-2008, she worked in many executive leadership roles at J&J in the Pharmaceutical and Consumer businesses, including serving as J&J's Vice President for Medical & Regulatory Affairs for the over-the-counter drugs business.Prior to joining J&J, Ms. Baylor-Henry worked for the U.S. Food & Drug Administration (FDA). During her career at FDA, she served in many roles, most notably, FDA's National Health Fraud Coordinator and, within the Center for Drugs, as the Director of the Division of Drug Marketing, Advertising, and Communications.Ms. Baylor-Henry previously served as the Board Chair for the Food and Drug Law Institute (FDLI) and was a member of the board of Flame Biosciences. Additionally, she served as the President and Chair of the board for the Drug Information Association (DIA), where she is currently serving as a Fellow. Ms. Baylor-Henry is a Trustee for Howard University, as well as the Chair of the Board of Visitors for Howard University's College of Pharmacy. In addition, she is an independent director for scPharmaceuticals, Apyx Medical, Lantheus Holdings, Inc. and PolarityTE, all publicly traded companies. Ms. Baylor-Henry is a member of the board of directors for several not-for-profit companies, including The Partnership, Mass Eye & Ear Hospital, and Dress for Success Boston.Ms. Baylor-Henry received her Pharmacy degree from Howard University's College of Pharmacy and her law degree from Catholic University's Columbus School of Law. - Minnie V. Baylor Henry，自2021年6月起担任Paratek Pharmaceuticals, Inc.董事会成员。自2015年以来，贝勒-亨利女士一直担任B-Henry & Associates的总裁，该公司是一家专注于为生命科学公司提供监管和合规战略服务的咨询公司。在担任现职之前，她曾在2011年至2015年期间担任强生（强生）医疗器械和诊断业务的全球监管事务副总裁。在2011年回到强生之前，贝勒-亨利女士曾在德勤担任监管和资本市场咨询全国总监，在监管生命科学领域有着成功的实践经验。从1999年到2008年，她在强生的制药和消费者业务部门担任过许多行政领导职务，包括担任强生负责非处方药业务的医疗和监管事务副总裁。在加入强生之前，贝勒-亨利曾在美国食品和药物管理局（FDA）工作。在FDA的职业生涯中，她担任过许多职务，最著名的是FDA的National Health欺诈协调员，以及在药品中心担任药品营销、广告和传播司司长。Baylor-Henry曾担任食品和药品法律研究所（FDLI）的董事会主席，也是Flame Biosciences的董事会成员。此外，她还担任药物信息协会（DIA）的主席和理事会主席，目前担任该协会的研究员。Baylor-Henry女士是霍华德大学的受托人，也是霍华德大学药学院访问委员会主席。此外，她还是scPharmaceuticals、Apyx Medical、Lantheus控股和PolarityTE的独立董事，这些公司都是上市公司。贝勒-亨利女士是多家非盈利公司的董事会成员，包括The Partnership、Mass Eye & Ear Hospital和Dress for Success Boston。贝勒-亨利在霍华德大学药学院获得药学学位，在天主教大学哥伦布法学院获得法学学位。
- Minnie V. Baylor Henry,has served on Paratek Pharmaceuticals, Inc. Board since June 2021. Ms. Baylor-Henry has served as the President of B-Henry & Associates, a consulting firm focused on providing regulatory and compliance strategy services to life sciences companies, since 2015. Prior to assuming her current role, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson's (J&J) Medical Devices & Diagnostics business from 2011 to 2015.Before returning to J&J in 2011, Ms. Baylor-Henry was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche, with a successful practice that focused on regulatory life sciences. From 1999-2008, she worked in many executive leadership roles at J&J in the Pharmaceutical and Consumer businesses, including serving as J&J's Vice President for Medical & Regulatory Affairs for the over-the-counter drugs business.Prior to joining J&J, Ms. Baylor-Henry worked for the U.S. Food & Drug Administration (FDA). During her career at FDA, she served in many roles, most notably, FDA's National Health Fraud Coordinator and, within the Center for Drugs, as the Director of the Division of Drug Marketing, Advertising, and Communications.Ms. Baylor-Henry previously served as the Board Chair for the Food and Drug Law Institute (FDLI) and was a member of the board of Flame Biosciences. Additionally, she served as the President and Chair of the board for the Drug Information Association (DIA), where she is currently serving as a Fellow. Ms. Baylor-Henry is a Trustee for Howard University, as well as the Chair of the Board of Visitors for Howard University's College of Pharmacy. In addition, she is an independent director for scPharmaceuticals, Apyx Medical, Lantheus Holdings, Inc. and PolarityTE, all publicly traded companies. Ms. Baylor-Henry is a member of the board of directors for several not-for-profit companies, including The Partnership, Mass Eye & Ear Hospital, and Dress for Success Boston.Ms. Baylor-Henry received her Pharmacy degree from Howard University's College of Pharmacy and her law degree from Catholic University's Columbus School of Law.
- Phuong Khanh Morrow
-
Phuong Khanh Morrow，现任武田肿瘤治疗领域单位（OTAU）负责人，负责公司的肿瘤研发战略和发展组合（2024年1月至今）；前首席医疗官CRISPR Therapeutics，在那里她领导了一支由医生、科学家和开发团队成员组成的跨职能团队，负责监督跨越血液学、肿瘤学、糖尿病和心血管疾病的临床项目的端到端开发，帮助引导了exa-cel的开发和随后的批准，首个获得FDA批准的CRISPR编辑基因疗法，用于治疗严重的镰状细胞病和输血依赖性β-地中海贫血（2022年5月至2024年1月）；前副总裁兼血液学、胃肠道肿瘤学、GU肿瘤学和骨病全球治疗领域负责人，安进（2012年3月至2022年5月）；曾任得克萨斯大学MD安德森癌症中心乳腺医学肿瘤学系助理教授（2006年6月至2012年2月）。贝勒医学院内科住院医师；休斯顿得克萨斯大学医学院医学博士。
Phuong Khanh Morrow,Current Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, where she is responsible for the company's oncology research and development strategy and development portfolio (January 2024 to present);Former Chief Medical Officer, CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and development team members overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular diseases, helped to shepherd the development and subsequent approval of exa-cel, the first CRISPR-edited gene therapy to be approved by the FDA for the treatment of severe sickle cell disease and transfusion-dependent beta-thalassemia (May 2022 to January 2024);Former Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases, Amgen (March 2012 to May 2022);Former Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center (June 2006 to February 2012).Internal medicine residency at Baylor College of Medicine;M.D., University of Texas Medical School at Houston. - Phuong Khanh Morrow，现任武田肿瘤治疗领域单位（OTAU）负责人，负责公司的肿瘤研发战略和发展组合（2024年1月至今）；前首席医疗官CRISPR Therapeutics，在那里她领导了一支由医生、科学家和开发团队成员组成的跨职能团队，负责监督跨越血液学、肿瘤学、糖尿病和心血管疾病的临床项目的端到端开发，帮助引导了exa-cel的开发和随后的批准，首个获得FDA批准的CRISPR编辑基因疗法，用于治疗严重的镰状细胞病和输血依赖性β-地中海贫血（2022年5月至2024年1月）；前副总裁兼血液学、胃肠道肿瘤学、GU肿瘤学和骨病全球治疗领域负责人，安进（2012年3月至2022年5月）；曾任得克萨斯大学MD安德森癌症中心乳腺医学肿瘤学系助理教授（2006年6月至2012年2月）。贝勒医学院内科住院医师；休斯顿得克萨斯大学医学院医学博士。
- Phuong Khanh Morrow,Current Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, where she is responsible for the company's oncology research and development strategy and development portfolio (January 2024 to present);Former Chief Medical Officer, CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and development team members overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular diseases, helped to shepherd the development and subsequent approval of exa-cel, the first CRISPR-edited gene therapy to be approved by the FDA for the treatment of severe sickle cell disease and transfusion-dependent beta-thalassemia (May 2022 to January 2024);Former Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases, Amgen (March 2012 to May 2022);Former Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center (June 2006 to February 2012).Internal medicine residency at Baylor College of Medicine;M.D., University of Texas Medical School at Houston.
- Minnie V. Baylor Henry
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Julie M. Eastland
-
Julie M. Eastland，现任Zentalis公司总裁兼首席执行官；Harpoon Therapeutics前首席执行官（2021年11月至2024年3月）；Rainier Therapeutics，Inc.前首席财务和业务官（2018年至2020年）；Cascadian Therapeutics, Inc.（2010年9月至2018年3月）；VLST Corporation前首席财务官兼财务副总裁（2006年1月至2010年9月）；Dendreon Corporation前战略规划副总裁（2000年10月至2005年10月）；安进前财务总监（1996年3月至1998年4月）。学士学位，科罗拉多州立大学金融学；苏格兰爱丁堡大学赫瑞瓦特大学MBA。
Julie M. Eastland,Current President and CEO, Zentalis Corporation;Former CEO, Harpoon Therapeutics (November 2021 until March 2024);Former Chief Financial and Business Officer, Rainier Therapeutics, Inc. (2018 to 2020);Former Chief Business Officer and Chief Financial Officer, Cascadian Therapeutics, Inc. (September 2010 until March 2018);Former CFO and Vice President of Finance, VLST Corporation (January 2006 until September 2010);Former Vice President of Strategic Planning, Dendreon Corporation (October 2000 until October 2005);Former Controller, Amgen (March 1996 to April 1998).B.S., Finance, Colorado State University;MBA, Heriot-Watt University of the Edinburgh University in Scotland. - Julie M. Eastland，现任Zentalis公司总裁兼首席执行官；Harpoon Therapeutics前首席执行官（2021年11月至2024年3月）；Rainier Therapeutics，Inc.前首席财务和业务官（2018年至2020年）；Cascadian Therapeutics, Inc.（2010年9月至2018年3月）；VLST Corporation前首席财务官兼财务副总裁（2006年1月至2010年9月）；Dendreon Corporation前战略规划副总裁（2000年10月至2005年10月）；安进前财务总监（1996年3月至1998年4月）。学士学位，科罗拉多州立大学金融学；苏格兰爱丁堡大学赫瑞瓦特大学MBA。
- Julie M. Eastland,Current President and CEO, Zentalis Corporation;Former CEO, Harpoon Therapeutics (November 2021 until March 2024);Former Chief Financial and Business Officer, Rainier Therapeutics, Inc. (2018 to 2020);Former Chief Business Officer and Chief Financial Officer, Cascadian Therapeutics, Inc. (September 2010 until March 2018);Former CFO and Vice President of Finance, VLST Corporation (January 2006 until September 2010);Former Vice President of Strategic Planning, Dendreon Corporation (October 2000 until October 2005);Former Controller, Amgen (March 1996 to April 1998).B.S., Finance, Colorado State University;MBA, Heriot-Watt University of the Edinburgh University in Scotland.
- Mary Anne Heino
-
Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC. - Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
- Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.
- Samuel Leno
-
Samuel Leno是董事，审计委员会主席，提名和公司治理委员会成员，自2012年5月起在董事会任职。Leno先生是一位战略执行官，在复杂的跨国公司拥有超过40年的经验。他最近担任Boston Scientific的执行Vice President和首席运营官。他此前曾担任执行Vice President、财务和信息系统以及首席财务官。他于2011年12月退任Boston Scientific公司。加入Boston Scientific公司之前，雷诺先生曾担任齐默尔控股公司（Zimmer Holdings，Inc.）的执行Vice President、财务和企业服务及首席财务官，以及ArrowElectronics，Inc.、企业Express，Inc.和Coram梦百合的首席财务官职位。此前，他曾担任Baxter International，Inc.、American Hospital Supply Corporation的多种高级财务职务。他曾是Zest Anchors，Inc.的董事会主席和审计委员会主席。他此前曾任职Omnicare公司和Tomotherapy公司的董事会和审计委员会，也曾任职Endotronix公司的董事会。Leno先生曾在美国海军担任中尉，是一名越南老兵。他持有Northern Illinois University的会计理学学士学位，以及Roosevelt University的工商管理硕士学位。
Samuel Leno is a Director and the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee, serving on the Board since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He was the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University. - Samuel Leno是董事，审计委员会主席，提名和公司治理委员会成员，自2012年5月起在董事会任职。Leno先生是一位战略执行官，在复杂的跨国公司拥有超过40年的经验。他最近担任Boston Scientific的执行Vice President和首席运营官。他此前曾担任执行Vice President、财务和信息系统以及首席财务官。他于2011年12月退任Boston Scientific公司。加入Boston Scientific公司之前，雷诺先生曾担任齐默尔控股公司（Zimmer Holdings，Inc.）的执行Vice President、财务和企业服务及首席财务官，以及ArrowElectronics，Inc.、企业Express，Inc.和Coram梦百合的首席财务官职位。此前，他曾担任Baxter International，Inc.、American Hospital Supply Corporation的多种高级财务职务。他曾是Zest Anchors，Inc.的董事会主席和审计委员会主席。他此前曾任职Omnicare公司和Tomotherapy公司的董事会和审计委员会，也曾任职Endotronix公司的董事会。Leno先生曾在美国海军担任中尉，是一名越南老兵。他持有Northern Illinois University的会计理学学士学位，以及Roosevelt University的工商管理硕士学位。
- Samuel Leno is a Director and the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee, serving on the Board since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He was the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University.
高管简历
中英对照 | 中文 | 英文- Robert J. Marshall, Jr.
Robert J.Marshall，Jr.于2018年9月加入Lantheus，担任首席财务官兼财务主管。在加入Lantheus之前，Marshall先生在齐默巴奥米特控股公司公司工作了16年，该公司是一家在肌肉骨骼健康方面处于领先地位的全球性医疗设备公司。他曾担任多种高级领导职务，包括Vice President、投资者关系和公司财务主管，最近担任美国、加拿大和拉丁美洲商业市场的美洲金融Vice President。任职Zimmer Biomet公司之前，他曾任职Brown&Williamson Tobacco公司（British American Tobacco，P.L.C.的子公司，位于肯塔基州路易斯维尔），在那里他曾担任多种职务，并不断被提拔。Marshall先生持有南本德印第安纳大学（Indiana University，South Bend）的工商管理硕士学位，以及圣母大学（University of Notre Dame）的金融学工商管理学士学位。他还持有CFA称号。
Robert J. Marshall, Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Mr. Marshall was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. He also holds the CFA designation.- Robert J.Marshall，Jr.于2018年9月加入Lantheus，担任首席财务官兼财务主管。在加入Lantheus之前，Marshall先生在齐默巴奥米特控股公司公司工作了16年，该公司是一家在肌肉骨骼健康方面处于领先地位的全球性医疗设备公司。他曾担任多种高级领导职务，包括Vice President、投资者关系和公司财务主管，最近担任美国、加拿大和拉丁美洲商业市场的美洲金融Vice President。任职Zimmer Biomet公司之前，他曾任职Brown&Williamson Tobacco公司（British American Tobacco，P.L.C.的子公司，位于肯塔基州路易斯维尔），在那里他曾担任多种职务，并不断被提拔。Marshall先生持有南本德印第安纳大学（Indiana University，South Bend）的工商管理硕士学位，以及圣母大学（University of Notre Dame）的金融学工商管理学士学位。他还持有CFA称号。
- Robert J. Marshall, Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Mr. Marshall was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. He also holds the CFA designation.
- Jamie Spaeth
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Daniel M. Niedzwiecki
Daniel M. Niedzwiecki自2023年3月起担任Lantheus Holdings, Inc.首席行政官、总法律顾问和公司秘书，并在该职位上监督法律、道德与合规、ERM、人力资源、信息技术和企业传播职能。Niedzwiecki于2013年加入Lantheus，自最初加入公司担任助理总法律顾问和助理公司秘书以来，一直担任越来越多的职责。在加入Lantheus之前，Niedzwiecki先生是Weil，Gotshal & Manges的私募股权和并购律师，在此之前，是Palmer & Dodge的证券和交易律师。Niedzwiecki先生开始了他的法律职业生涯，为美国麻萨诸塞州地区法院尊敬的Frank H. Freedman担任书记员。Niedzwiecki先生获得波士顿大学法学院法学博士学位和威廉姆斯学院经济学文学士学位。
Daniel M. Niedzwiecki has served as Lantheus Holdings, Inc. Chief Administrative Officer, General Counsel and Corporate Secretary since March 2023, and in that role has overseen the Legal, Ethics and Compliance, ERM, Human Resources, Information Technology and Corporate Communications functions.Mr. Niedzwiecki joined Lantheus in 2013 and has served in positions of increasing responsibilities since originally joining the Company as Assistant General Counsel and Assistant Corporate Secretary. Prior to joining Lantheus, Mr. Niedzwiecki was a private equity and mergers and acquisitions attorney with Weil, Gotshal & Manges and, prior to that, a securities and transactional attorney at Palmer & Dodge. Mr. Niedzwiecki started his legal career clerking for the Honorable Frank H. Freedman of the United States District Court for the District of Massachusetts. Mr. Niedzwiecki received a Juris Doctor from Boston University School of Law and a Bachelor of Arts in Economics from Williams College.- Daniel M. Niedzwiecki自2023年3月起担任Lantheus Holdings, Inc.首席行政官、总法律顾问和公司秘书，并在该职位上监督法律、道德与合规、ERM、人力资源、信息技术和企业传播职能。Niedzwiecki于2013年加入Lantheus，自最初加入公司担任助理总法律顾问和助理公司秘书以来，一直担任越来越多的职责。在加入Lantheus之前，Niedzwiecki先生是Weil，Gotshal & Manges的私募股权和并购律师，在此之前，是Palmer & Dodge的证券和交易律师。Niedzwiecki先生开始了他的法律职业生涯，为美国麻萨诸塞州地区法院尊敬的Frank H. Freedman担任书记员。Niedzwiecki先生获得波士顿大学法学院法学博士学位和威廉姆斯学院经济学文学士学位。
- Daniel M. Niedzwiecki has served as Lantheus Holdings, Inc. Chief Administrative Officer, General Counsel and Corporate Secretary since March 2023, and in that role has overseen the Legal, Ethics and Compliance, ERM, Human Resources, Information Technology and Corporate Communications functions.Mr. Niedzwiecki joined Lantheus in 2013 and has served in positions of increasing responsibilities since originally joining the Company as Assistant General Counsel and Assistant Corporate Secretary. Prior to joining Lantheus, Mr. Niedzwiecki was a private equity and mergers and acquisitions attorney with Weil, Gotshal & Manges and, prior to that, a securities and transactional attorney at Palmer & Dodge. Mr. Niedzwiecki started his legal career clerking for the Honorable Frank H. Freedman of the United States District Court for the District of Massachusetts. Mr. Niedzwiecki received a Juris Doctor from Boston University School of Law and a Bachelor of Arts in Economics from Williams College.
- Jean Claude Provost
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Amanda Morgan
Amanda Morgan，于2022年11月加入Lantheus，担任商务高级副总裁，并晋升为首席商务官，2024年3月25日生效。Morgan女士是一位在医疗保健行业拥有超20年经验的高管，Morgan女士是一位经验丰富的商业领袖。在加入Lantheus之前，她是阿卡迪亚的首席营收和客户官，在那里她成功地领导了这家商业机构。在加入Acadia之前，Morgan女士曾在Shire plc担任逐渐具有挑战性的职务，包括美国销售主管和美国患者服务主管，为数十亿美元的制药企业提供支持。Morgan女士拥有爱荷华大学工商管理学士学位。
Amanda Morgan,joined Lantheus in November 2022 as Senior Vice President, Commercial and was promoted to Chief Commercial Officer, effective March 25, 2024. Ms. Morgan is an executive with over 20 years of experience in the healthcare industry, Ms. Morgan is a seasoned commercial leader. Prior to joining Lantheus, she was Chief Revenue and Customer Officer at Acadia Pharmaceuticals, where she successfully led the commercial organization. Prior to her tenure at Acadia, Ms. Morgan held progressively challenging roles at Shire Plc, including U.S. Head of Sales and U.S. Head of Patient Services, supporting multi-billion-dollar pharmaceutical businesses. Ms. Morgan holds a Bachelor of Business Administration from The University of Iowa.- Amanda Morgan，于2022年11月加入Lantheus，担任商务高级副总裁，并晋升为首席商务官，2024年3月25日生效。Morgan女士是一位在医疗保健行业拥有超20年经验的高管，Morgan女士是一位经验丰富的商业领袖。在加入Lantheus之前，她是阿卡迪亚的首席营收和客户官，在那里她成功地领导了这家商业机构。在加入Acadia之前，Morgan女士曾在Shire plc担任逐渐具有挑战性的职务，包括美国销售主管和美国患者服务主管，为数十亿美元的制药企业提供支持。Morgan女士拥有爱荷华大学工商管理学士学位。
- Amanda Morgan,joined Lantheus in November 2022 as Senior Vice President, Commercial and was promoted to Chief Commercial Officer, effective March 25, 2024. Ms. Morgan is an executive with over 20 years of experience in the healthcare industry, Ms. Morgan is a seasoned commercial leader. Prior to joining Lantheus, she was Chief Revenue and Customer Officer at Acadia Pharmaceuticals, where she successfully led the commercial organization. Prior to her tenure at Acadia, Ms. Morgan held progressively challenging roles at Shire Plc, including U.S. Head of Sales and U.S. Head of Patient Services, supporting multi-billion-dollar pharmaceutical businesses. Ms. Morgan holds a Bachelor of Business Administration from The University of Iowa.
- Cheryl Ball
谢丽尔·鲍尔于2019年加入蓝特，担任首席战略官和企业发展主管。Ball女士为公司带来了30多年的领导力、企业战略和产品组合规划、治疗领域战略、BD搜索和评估以及新产品规划。在Lanthe，她领导企业和BINCE发展战略、投资组合治理和联盟管理。在加入Lanthe之前，Ball女士领导了PPD的全球市场准入咨询业务，为制药公司规划肿瘤学、神经科学和罕见病领域的新产品提供全球市场准入、定价和证据生成策略。She previoly担任阿斯利康新机遇领域的领导者，专注于识别既定核心BINES之外的增长和BD机会。在加入阿斯利康之前，Ball女士曾在生命科学战略咨询公司担任领导职务，包括Decision Reseces Group和Quintiles（现为艾昆纬）。她的职业生涯始于企业金融，并获得了乔治敦大学国际金融和商业专业的外交服务理学学士学位。
Cheryl Ball joined Lanthe in 2019 and serves as Chief Strategy Officer and Head of Corporate Development. At Lanthe, she leads corporate and biness development strategy, portfolio governance and alliance management. Before joining Lanthe, Ms. Ball led PPD's Global Market Access Consulting Practice, providing global market access, pricing and evidence generation strategy to pharmaceutical companies in planning for new products in oncology, neuroscience and rare diseases. She previoly served as a leader in AstraZeneca's New Opportunities segment, focused on identifying growth and BD opportunities outside of the established core biness. Prior to AstraZeneca, Ms. Ball held leadership roles in life sciences strategy consultancies, including Decision Resources Group and Quintiles (now IQVIA). She started her career in corporate finance and received a Bachelor of Science in Foreign Service with a concentration in international finance and commerce from Georgetown University.- 谢丽尔·鲍尔于2019年加入蓝特，担任首席战略官和企业发展主管。Ball女士为公司带来了30多年的领导力、企业战略和产品组合规划、治疗领域战略、BD搜索和评估以及新产品规划。在Lanthe，她领导企业和BINCE发展战略、投资组合治理和联盟管理。在加入Lanthe之前，Ball女士领导了PPD的全球市场准入咨询业务，为制药公司规划肿瘤学、神经科学和罕见病领域的新产品提供全球市场准入、定价和证据生成策略。She previoly担任阿斯利康新机遇领域的领导者，专注于识别既定核心BINES之外的增长和BD机会。在加入阿斯利康之前，Ball女士曾在生命科学战略咨询公司担任领导职务，包括Decision Reseces Group和Quintiles（现为艾昆纬）。她的职业生涯始于企业金融，并获得了乔治敦大学国际金融和商业专业的外交服务理学学士学位。
- Cheryl Ball joined Lanthe in 2019 and serves as Chief Strategy Officer and Head of Corporate Development. At Lanthe, she leads corporate and biness development strategy, portfolio governance and alliance management. Before joining Lanthe, Ms. Ball led PPD's Global Market Access Consulting Practice, providing global market access, pricing and evidence generation strategy to pharmaceutical companies in planning for new products in oncology, neuroscience and rare diseases. She previoly served as a leader in AstraZeneca's New Opportunities segment, focused on identifying growth and BD opportunities outside of the established core biness. Prior to AstraZeneca, Ms. Ball held leadership roles in life sciences strategy consultancies, including Decision Resources Group and Quintiles (now IQVIA). She started her career in corporate finance and received a Bachelor of Science in Foreign Service with a concentration in international finance and commerce from Georgetown University.
- Ludger Dinkelborg
Ludger Dinkelborg加入LANTER，担任研发主管，2025年8月1日生效。Dr. Dinkelborg previoly担任Life Molecular Imaging，Ltd.的首席执行官和董事总经理，该公司于2025年7月被Lanthe收购。他带来了30多年的制药工业研发经验。在共同创立Life Molecular之前，Dinkelborg博士曾在Bayer HealthCare担任诊断成像研究主管和分子成像主管。作为副总裁兼诊断成像研究负责人，拜耳医药保健的f全球研究领域之一，他的研究包括用于计算机断层扫描和磁共振的造影剂，以及分子成像中的靶向剂。他在德国杜塞尔多夫的海因里希·海涅大学获得生物学博士学位，并留在多特蒙德的马克斯·普朗克分子生理学研究所担任客座研究员。他成为了Konrad Adenauer基金会的研究员，参加了Cranfield Schering University CSE for managers，并参加了位于加利福尼亚州斯坦福的Biness斯坦福研究生院的斯坦福高管项目。
Ludger Dinkelborg joined Lanthe as Head of Research and Development, effective August 1, 2025. Dr. Dinkelborg was previoly the CEO and Managing Director of Life Molecular Imaging, Ltd., a company acquired by Lanthe in July 2025. Before co founding Life Molecular, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer HealthCare. As Vice President and Head of Diagnostic Imaging Research, one of f global research areas of Bayer HealthCare, his research comprised contrast media for computed tomography and magnetic resonance, as ll as targeted agents in molecular imaging. He received his PhD in biology at Heinrich Heine University, Düsseldorf, Germany, and stayed as guest researcher at the Max Planck Institute of Molecular Physiology in Dortmund. He became a fellow of the Konrad Adenauer Foundation, attended the Cranfield Schering University cse for managers and participated in the Stanford Executive Program at the Stanford Graduate School of Biness in Stanford, CA.- Ludger Dinkelborg加入LANTER，担任研发主管，2025年8月1日生效。Dr. Dinkelborg previoly担任Life Molecular Imaging，Ltd.的首席执行官和董事总经理，该公司于2025年7月被Lanthe收购。他带来了30多年的制药工业研发经验。在共同创立Life Molecular之前，Dinkelborg博士曾在Bayer HealthCare担任诊断成像研究主管和分子成像主管。作为副总裁兼诊断成像研究负责人，拜耳医药保健的f全球研究领域之一，他的研究包括用于计算机断层扫描和磁共振的造影剂，以及分子成像中的靶向剂。他在德国杜塞尔多夫的海因里希·海涅大学获得生物学博士学位，并留在多特蒙德的马克斯·普朗克分子生理学研究所担任客座研究员。他成为了Konrad Adenauer基金会的研究员，参加了Cranfield Schering University CSE for managers，并参加了位于加利福尼亚州斯坦福的Biness斯坦福研究生院的斯坦福高管项目。
- Ludger Dinkelborg joined Lanthe as Head of Research and Development, effective August 1, 2025. Dr. Dinkelborg was previoly the CEO and Managing Director of Life Molecular Imaging, Ltd., a company acquired by Lanthe in July 2025. Before co founding Life Molecular, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer HealthCare. As Vice President and Head of Diagnostic Imaging Research, one of f global research areas of Bayer HealthCare, his research comprised contrast media for computed tomography and magnetic resonance, as ll as targeted agents in molecular imaging. He received his PhD in biology at Heinrich Heine University, Düsseldorf, Germany, and stayed as guest researcher at the Max Planck Institute of Molecular Physiology in Dortmund. He became a fellow of the Konrad Adenauer Foundation, attended the Cranfield Schering University cse for managers and participated in the Stanford Executive Program at the Stanford Graduate School of Biness in Stanford, CA.
- Mary Anne Heino
Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.- Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
- Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.